{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:47Z","timestamp":1792097327672,"version":"4.4.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03416-1","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:08:18Z","timestamp":1789448898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7200-9658","authenticated-orcid":false,"given":"Sarenur","family":"Tekiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3218-5212","authenticated-orcid":false,"given":"Rumeysa Berra","family":"Karata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9920-5931","authenticated-orcid":false,"given":"Yaren","family":"Alras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3478-9754","authenticated-orcid":false,"given":"Kaan","family":"Z\u0131k\u015fahna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7036-1115","authenticated-orcid":false,"given":"Selim","family":"Merdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-5638","authenticated-orcid":false,"given":"Murat","family":"Ihlamur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"11","key":"3416_CR1","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","volume":"56","author":"RJ Zhang","year":"2024","unstructured":"Zhang RJ, Kim TK. VISTA-mediated immune evasion in cancer. Exp Mol Med. 2024;56(11):2348\u201356. https:\/\/doi.org\/10.1038\/s12276-024-01336-6.","journal-title":"Exp Mol Med"},{"key":"3416_CR2","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699. https:\/\/doi.org\/10.3389\/fimmu.2025.1688699.","journal-title":"Front Immunol"},{"issue":"29","key":"3416_CR3","doi-asserted-by":"publisher","first-page":"eadm8660","DOI":"10.1126\/sciadv.adm8660","volume":"10","author":"I Vanmeerbeek","year":"2024","unstructured":"Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, Pretto S, Zhao S, Cafarello ST, Verelst J, Jacquemyn M, Pociupany M, Boon L, Schlenner SM, Tejpar S, Daelemans D, Mazzone M, Garg AD. Targeting conserved TIM3(+)VISTA(+) tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci Adv. 2024;10(29):eadm8660. https:\/\/doi.org\/10.1126\/sciadv.adm8660.","journal-title":"Sci Adv"},{"key":"3416_CR4","doi-asserted-by":"publisher","unstructured":"ElTanbouly MA, Zhao Y, Nowak E, Li J, Schaafsma E, Le Mercier I, Ceeraz S, Lines JL, Peng C, Carriere C, Huang X, Day M, Koehn B, Lee SW, Silva Morales M, Hogquist KA, Jameson SC, Mueller D, Rothstein J, Blazar BR, Cheng C, Noelle RJ. VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance. Science. 2020;367(6475). https:\/\/doi.org\/10.1126\/science.aay0524.","DOI":"10.1126\/science.aay0524"},{"key":"3416_CR5","doi-asserted-by":"publisher","first-page":"116100","DOI":"10.1016\/j.bcp.2024.116100","volume":"222","author":"S Li","year":"2024","unstructured":"Li S, Wang G, Ren Y, Liu X, Wang Y, Li J, Liu H, Yang J, Xing J, Zhang Y, He C, Xu S, Hou X, Li N. Expression and function of VISTA on myeloid cells. Biochem Pharmacol. 2024;222:116100. https:\/\/doi.org\/10.1016\/j.bcp.2024.116100.","journal-title":"Biochem Pharmacol"},{"key":"3416_CR6","doi-asserted-by":"publisher","first-page":"1194421","DOI":"10.3389\/fimmu.2023.1194421","volume":"14","author":"M Zheng","year":"2023","unstructured":"Zheng M, Zhang Z, Yu L, Wang Z, Dong Y, Tong A, Yang H. Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection. Front Immunol. 2023;14:1194421. https:\/\/doi.org\/10.3389\/fimmu.2023.1194421.","journal-title":"Front Immunol"},{"issue":"1","key":"3416_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","volume":"276","author":"EC Nowak","year":"2017","unstructured":"Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, Kuta A, Le Mercier I, Cheng C, Noelle RJ. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276(1):66\u201379. https:\/\/doi.org\/10.1111\/imr.12525.","journal-title":"Immunol Rev"},{"issue":"1","key":"3416_CR8","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1038\/s41598-017-06410-w","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang Q, He J, Flies DB, Luo L, Chen L. Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. Sci Rep. 2017;7(1):6086. https:\/\/doi.org\/10.1038\/s41598-017-06410-w.","journal-title":"Sci Rep"},{"issue":"10","key":"3416_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","volume":"28","author":"N Mehta","year":"2019","unstructured":"Mehta N, Maddineni S, Mathews II, Andres Parra Sperberg R, Huang PS, Cochran JR. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation. Cell Rep. 2019;28(10):2509\u2013e25162505. https:\/\/doi.org\/10.1016\/j.celrep.2019.07.073.","journal-title":"Cell Rep"},{"key":"3416_CR10","doi-asserted-by":"publisher","first-page":"101308","DOI":"10.1016\/j.smim.2019.101308","volume":"42","author":"MA ElTanbouly","year":"2019","unstructured":"ElTanbouly MA, Croteau W, Noelle RJ, Lines JL. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol. 2019;42:101308. https:\/\/doi.org\/10.1016\/j.smim.2019.101308.","journal-title":"Semin Immunol"},{"key":"3416_CR11","doi-asserted-by":"publisher","first-page":"1086102","DOI":"10.3389\/fimmu.2023.1086102","volume":"14","author":"AS Martin","year":"2023","unstructured":"Martin AS, Molloy M, Ugolkov A, von Roemeling RW, Noelle RJ, Lewis LD, Johnson M, Radvanyi L, Martell RE. VISTA expression and patient selection for immune-based anticancer therapy. Front Immunol. 2023;14:1086102. https:\/\/doi.org\/10.3389\/fimmu.2023.1086102.","journal-title":"Front Immunol"},{"issue":"1","key":"3416_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","volume":"156","author":"J Wang","year":"2019","unstructured":"Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C, Guan J, Singh R, Rollins S, Solorz A, Bi M, Li J, Grabowski D, Dirkx J, Tracy C, Stuart T, Ellinghuysen C, Desmond D, Foster C, Kalabokis V. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology. 2019;156(1):74\u201385. https:\/\/doi.org\/10.1111\/imm.13001.","journal-title":"Immunology"},{"issue":"18","key":"3416_CR13","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1158\/0008-5472.Can-24-4774","volume":"85","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Andoh T, Charles F, Reddy P, Paul K, Goar H, Durdana I, Golder CJ, Hardy AN, Juntilla MM, Yang SR, Lin CY, Sagiv-Barfi I, Geller BS, Moore S, Thakkar D, Boyd-Kirkup JD, Peng Y, Ford JM, Telli ML, Zhang S, Kurian AW, West RB, Yue T, Lipchik AM, Snyder MP, Gruber JJ. A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression. Cancer Res. 2025;85(18):3399\u2013415. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-4774.","journal-title":"Cancer Res"},{"issue":"7779","key":"3416_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RY, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang YK, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370. https:\/\/doi.org\/10.1038\/s41586-019-1674-5.","journal-title":"Nature"},{"key":"3416_CR15","doi-asserted-by":"publisher","unstructured":"Rogers BM, Smith L, Dezso Z, Shi X, DiGiammarino E, Nguyen D, Sethuraman S, Zheng P, Choi D, Zhang D, Nguyen A, McGuire K, Liu W, Chung N, Chao DT, Ye S, Starbeck-Miller GR. VISTA is an activating receptor in human monocytes. J Exp Med. 2021;218(8). https:\/\/doi.org\/10.1084\/jem.20201601.","DOI":"10.1084\/jem.20201601"},{"issue":"4","key":"3416_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s10637-022-01244-4","volume":"40","author":"W Chen","year":"2022","unstructured":"Chen W, Qie C, Hu X, Wang L, Jiang J, Liu W, Liu J. A small molecule inhibitor of VSIG-8 prevents its binding to VISTA. Invest New Drugs. 2022;40(4):690\u20139. https:\/\/doi.org\/10.1007\/s10637-022-01244-4.","journal-title":"Invest New Drugs"},{"key":"3416_CR17","doi-asserted-by":"publisher","first-page":"580557","DOI":"10.3389\/fimmu.2020.580557","volume":"11","author":"IM Yasinska","year":"2020","unstructured":"Yasinska IM, Meyer NH, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M, Fiedler W, Wellbrock J, Desmet C, Calzolai L, Varani L, Berger SM, Raap U, Gibbs BF, Fasler-Kan E, Sumbayev VV. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. Front Immunol. 2020;11:580557. https:\/\/doi.org\/10.3389\/fimmu.2020.580557.","journal-title":"Front Immunol"},{"issue":"95","key":"3416_CR18","doi-asserted-by":"publisher","first-page":"eadi7418","DOI":"10.1126\/sciimmunol.adi7418","volume":"9","author":"HM Ta","year":"2024","unstructured":"Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, Parthasarathy PB, Patnaik S, Delaney E, Gilmour C, Zakeri A, Shukla N, Rupani A, Phoon YP, Liu C, Avril S, Gastman B, Chan T, Wang LL. LRIG1 engages ligand VISTA and impairs tumor-specific CD8(+) T cell responses. Sci Immunol. 2024;9(95):eadi7418. https:\/\/doi.org\/10.1126\/sciimmunol.adi7418.","journal-title":"Sci Immunol"},{"issue":"38","key":"3416_CR19","doi-asserted-by":"publisher","first-page":"16194","DOI":"10.1021\/jacs.0c07276","volume":"142","author":"MT Gabr","year":"2020","unstructured":"Gabr MT, Gambhir SS. Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA). J Am Chem Soc. 2020;142(38):16194\u20138. https:\/\/doi.org\/10.1021\/jacs.0c07276.","journal-title":"J Am Chem Soc"},{"issue":"7779","key":"3416_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RYC, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang Y-K, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370. https:\/\/doi.org\/10.1038\/s41586-019-1674-5.","journal-title":"Nature"},{"issue":"95","key":"3416_CR21","doi-asserted-by":"publisher","first-page":"eadi7418","DOI":"10.1126\/sciimmunol.adi7418","volume":"9","author":"HM Ta","year":"2024","unstructured":"Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, Parthasarathy PB, Patnaik S, Delaney E, Gilmour C, Zakeri A, Shukla N, Rupani A, Phoon YP, Liu C, Avril S, Gastman B, Chan T, Wang LL. LRIG1 engages ligand VISTA and impairs tumor-specific CD8\u2009<\u2009sup>+\u2009T cell responses. Sci Immunol. 2024;9(95):eadi7418. https:\/\/doi.org\/10.1126\/sciimmunol.adi7418.","journal-title":"Sci Immunol"},{"key":"3416_CR22","doi-asserted-by":"publisher","first-page":"108323","DOI":"10.1016\/j.bioorg.2025.108323","volume":"157","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Shi Y, Shao C, Tang W, Liu H, Chen J, Wang S, Cheng B. Discovery of bifunctional small molecules targeting PD-L1\/VISTA with favorable pharmacokinetics for cancer immunotherapy. Bioorg Chem. 2025;157:108323. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108323.","journal-title":"Bioorg Chem"},{"issue":"6","key":"3416_CR23","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.4110\/in.2025.25.e44","volume":"25","author":"H Laraki","year":"2025","unstructured":"Laraki H, Rezouki I, Choukri K, Badou A. VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies. Immune Netw. 2025;25(6):e44. https:\/\/doi.org\/10.4110\/in.2025.25.e44.","journal-title":"Immune Netw"},{"issue":"1","key":"3416_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","volume":"120","author":"K Mulati","year":"2019","unstructured":"Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115\u201327. https:\/\/doi.org\/10.1038\/s41416-018-0313-5.","journal-title":"Br J Cancer"},{"issue":"7","key":"3416_CR25","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.Can-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O\u2019Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74(7):1924\u201332. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-1504.","journal-title":"Cancer Res"},{"issue":"10","key":"3416_CR26","doi-asserted-by":"publisher","first-page":"e109103","DOI":"10.1371\/journal.pone.0109103","volume":"9","author":"P Bharaj","year":"2014","unstructured":"Bharaj P, Chahar HS, Alozie OK, Rodarte L, Bansal A, Goepfert PA, Dwivedi A, Manjunath N, Shankar P. Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PLoS ONE. 2014;9(10):e109103. https:\/\/doi.org\/10.1371\/journal.pone.0109103.","journal-title":"PLoS ONE"},{"key":"3416_CR27","doi-asserted-by":"publisher","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnstr\u00f6m H, Glimelius B, Sj\u00f6blom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352). https:\/\/doi.org\/10.1126\/science.aan2507.","DOI":"10.1126\/science.aan2507"},{"issue":"1","key":"3416_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10565-024-09852-x","volume":"40","author":"J-w Di","year":"2024","unstructured":"Di J-w, Wang Y-x, Ma R-x, Luo Z-j, Chen W-t, Liu W-m, Yuan D-y, Zhang Y-y, Wu Y-h, Chen C-p, Liu J. Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma. Cell Biol Toxicol. 2024;40(1):12. https:\/\/doi.org\/10.1007\/s10565-024-09852-x.","journal-title":"Cell Biol Toxicol"},{"issue":"4","key":"3416_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","volume":"187","author":"DB Flies","year":"2011","unstructured":"Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(4):1537\u201341. https:\/\/doi.org\/10.4049\/jimmunol.1100660.","journal-title":"J Immunol"},{"issue":"10","key":"3416_CR30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00109-020-01968-x","volume":"98","author":"M Borggrewe","year":"2020","unstructured":"Borggrewe M, Kooistra SM, Noelle RJ, Eggen BJL, Laman JD. Exploring the VISTA of microglia: immune checkpoints in CNS inflammation. J Mol Med (Berl). 2020;98(10):1415\u201330. https:\/\/doi.org\/10.1007\/s00109-020-01968-x.","journal-title":"J Mol Med (Berl)"},{"issue":"29","key":"3416_CR31","doi-asserted-by":"publisher","first-page":"eadm8660","DOI":"10.1126\/sciadv.adm8660","volume":"10","author":"I Vanmeerbeek","year":"2024","unstructured":"Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, Pretto S, Zhao S, Cafarello ST, Verelst J, Jacquemyn M, Pociupany M, Boon L, Schlenner SM, Tejpar S, Daelemans D, Mazzone M, Garg AD. tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci Adv. 2024;10(29):eadm8660. https:\/\/doi.org\/10.1126\/sciadv.adm8660. \/sup%3EVISTA\u2009%3C\u2009sup%3E+. Targeting conserved TIM3\u2009<\u2009sup>+<","journal-title":"Sci Adv"},{"issue":"5","key":"3416_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551\u20135. https:\/\/doi.org\/10.1038\/nm.4308.","journal-title":"Nat Med"},{"issue":"5","key":"3416_CR33","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692\u20137. https:\/\/doi.org\/10.1073\/pnas.1811067116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3416_CR34","doi-asserted-by":"publisher","first-page":"e1293215","DOI":"10.1080\/2162402x.2017.1293215","volume":"6","author":"C B\u00f6ger","year":"2017","unstructured":"B\u00f6ger C, Behrens HM, Kr\u00fcger S, R\u00f6cken C. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1\/PD-1: A future perspective for a combined gastric cancer therapy? Oncoimmunology. 2017;6(4):e1293215. https:\/\/doi.org\/10.1080\/2162402x.2017.1293215.","journal-title":"Oncoimmunology"},{"issue":"11","key":"3416_CR35","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00262-018-2227-8","volume":"67","author":"S Xie","year":"2018","unstructured":"Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, Dong C, Yang Z, Ni L. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 2018;67(11):1685\u201394. https:\/\/doi.org\/10.1007\/s00262-018-2227-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3416_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","volume":"66","author":"L Wu","year":"2017","unstructured":"Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao L, Zhang WF, Liu B, Sun ZJ. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother. 2017;66(5):627\u201336. https:\/\/doi.org\/10.1007\/s00262-017-1968-0.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"3416_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/2326-6066.Cir-18-0489","volume":"7","author":"W Xu","year":"2019","unstructured":"Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, Miller HE, Olson M, Rajasekaran K, Ernstoff MS, Wang D, Malarkannan S, Wang L. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunol Res. 2019;7(9):1497\u2013510. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0489.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3416_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","volume":"23","author":"N Shekari","year":"2023","unstructured":"Shekari N, Shanehbandi D, Kazemi T, Zarredar H, Baradaran B, Jalali SA. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. Cancer Cell Int. 2023;23(1):265. https:\/\/doi.org\/10.1186\/s12935-023-03116-0.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3416_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40164-024-00501-x","volume":"13","author":"Y Lin","year":"2024","unstructured":"Lin Y, Choukrani G, Dubbel L, Rockstein L, Freile JA, Qi Y, Wiersma V, Zhang H, Koch KW, Ammatuna E, Schuringa JJ, van Meerten T, Huls G, Bremer E. VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses. Exp Hematol Oncol. 2024;13(1):35. https:\/\/doi.org\/10.1186\/s40164-024-00501-x.","journal-title":"Exp Hematol Oncol"},{"issue":"8045","key":"3416_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-024-08194-2","volume":"637","author":"M Wagner","year":"2025","unstructured":"Wagner M, Nishikawa H, Koyasu S. Reinventing type 2 immunity in cancer. Nature. 2025;637(8045):296\u2013303. https:\/\/doi.org\/10.1038\/s41586-024-08194-2.","journal-title":"Nature"},{"key":"3416_CR41","doi-asserted-by":"publisher","first-page":"676181","DOI":"10.3389\/fimmu.2021.676181","volume":"12","author":"N Hosseinkhani","year":"2021","unstructured":"Hosseinkhani N, Derakhshani A, Shadbad MA, Argentiero A, Racanelli V, Kazemi T, Mokhtarzadeh A, Brunetti O, Silvestris N, Baradaran B. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol. 2021;12:676181. https:\/\/doi.org\/10.3389\/fimmu.2021.676181.","journal-title":"Front Immunol"},{"issue":"1","key":"3416_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang X, Zhang X, Li E, Zhang G, Wang X, Tang T, Bai X, Liang T. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol. 2020;13(1):83. https:\/\/doi.org\/10.1186\/s13045-020-00917-y.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3416_CR43","doi-asserted-by":"publisher","first-page":"102942","DOI":"10.1016\/j.esmoop.2024.102942","volume":"9","author":"D Nishizaki","year":"2024","unstructured":"Nishizaki D, Kurzrock R, Miyashita H, Adashek JJ, Lee S, Nikanjam M, Eskander RN, Patel H, Botta GP, Nesline MK, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kato S. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open. 2024;9(4):102942. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102942.","journal-title":"ESMO Open"},{"key":"3416_CR44","doi-asserted-by":"publisher","first-page":"583966","DOI":"10.3389\/fonc.2020.583966","volume":"10","author":"X Cao","year":"2020","unstructured":"Cao X, Ren X, Zhou Y, Mao F, Lin Y, Wu H, Sun Q. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer. Front Oncol. 2020;10:583966. https:\/\/doi.org\/10.3389\/fonc.2020.583966.","journal-title":"Front Oncol"},{"issue":"12","key":"3416_CR45","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.modpat.2025.100851","volume":"38","author":"Q Xie","year":"2025","unstructured":"Xie Q, Li J, Li J, Liu C, Li Y, Zeng H, Yu J, Wu Y, Chen K, Zhang Z, Wang B. Spatial Evaluation and Prognostic Significance of V-Domain Immunoglobulin Suppressor of T-Cell Activation (VISTA) in Human Resectable Cervical Carcinoma: Implications for Immune Activation and Suppression. Mod Pathol. 2025;38(12):100851. https:\/\/doi.org\/10.1016\/j.modpat.2025.100851.","journal-title":"Mod Pathol"},{"issue":"12","key":"3416_CR46","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666\u201376. https:\/\/doi.org\/10.1038\/modpathol.2017.89.","journal-title":"Mod Pathol"},{"issue":"7","key":"3416_CR47","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1078-0432.Ccr-17-2542","volume":"24","author":"F Villarroel-Espindola","year":"2018","unstructured":"Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially Resolved and Quantitative Analysis of VISTA\/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res. 2018;24(7):1562\u201373. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2542.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3416_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.Cir-22-0116","volume":"11","author":"E Schaafsma","year":"2023","unstructured":"Schaafsma E, Croteau W, ElTanbouly M, Nowak EC, Smits NC, Deng J, Sarde A, Webber CA, Rabadi D, Cheng C, Noelle R, Lines JL. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Cancer Immunol Res. 2023;11(1):38\u201355. https:\/\/doi.org\/10.1158\/2326-6066.Cir-22-0116.","journal-title":"Cancer Immunol Res"},{"issue":"6294","key":"3416_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aaf2403","volume":"353","author":"PL St\u00e5hl","year":"2016","unstructured":"St\u00e5hl PL, Salm\u00e9n F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, Giacomello S, Asp M, Westholm JO, Huss M, Mollbrink A, Linnarsson S, Codeluppi S, Borg \u00c5, Pont\u00e9n F, Costea PI, Sahl\u00e9n P, Mulder J, Bergmann O, Lundeberg J, Fris\u00e9n J. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78\u201382. https:\/\/doi.org\/10.1126\/science.aaf2403.","journal-title":"Science"},{"issue":"4","key":"3416_CR50","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","volume":"174","author":"Y Goltsev","year":"2018","unstructured":"Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, Black S, Nolan GP. Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. Cell. 2018;174(4):968\u2013e981915. https:\/\/doi.org\/10.1016\/j.cell.2018.07.010.","journal-title":"Cell"},{"issue":"4","key":"3416_CR51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.2869","volume":"11","author":"C Giesen","year":"2014","unstructured":"Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Sch\u00fcffler PJ, Grolimund D, Buhmann JM, Brandt S, Varga Z, Wild PJ, G\u00fcnther D, Bodenmiller B. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417\u201322. https:\/\/doi.org\/10.1038\/nmeth.2869.","journal-title":"Nat Methods"},{"issue":"3","key":"3416_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","volume":"42","author":"L Yuan","year":"2021","unstructured":"Yuan L, Tatineni J, Mahoney KM, Freeman GJ. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 2021;42(3):209\u201327. https:\/\/doi.org\/10.1016\/j.it.2020.12.008.","journal-title":"Trends Immunol"},{"issue":"1","key":"3416_CR53","doi-asserted-by":"publisher","first-page":"113661","DOI":"10.1016\/j.celrep.2023.113661","volume":"43","author":"K Zhang","year":"2024","unstructured":"Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, Branicky A, Zhao H, Juric I, Husich H, Parthasarathy PB, Rupani A, Drazba JA, Chakraborty AA, Ching-Cheng Huang S, Chan T, Avril S, Wang LL. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Rep. 2024;43(1):113661. https:\/\/doi.org\/10.1016\/j.celrep.2023.113661.","journal-title":"Cell Rep"},{"issue":"7","key":"3416_CR54","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.Cir-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng J, Li J, Sarde A, Lines JL, Lee YC, Qian DC, Pechenick DA, Manivanh R, Le Mercier I, Lowrey CH, Varn FS, Cheng C, Leib DA, Noelle RJ, Mabaera R. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunol Res. 2019;7(7):1079\u201390. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0507.","journal-title":"Cancer Immunol Res"},{"issue":"6230","key":"3416_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204.","journal-title":"Science"},{"issue":"9","key":"3416_CR56","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1172\/jci79434","volume":"126","author":"AW Lund","year":"2016","unstructured":"Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016;126(9):3389\u2013402. https:\/\/doi.org\/10.1172\/jci79434.","journal-title":"J Clin Invest"},{"key":"3416_CR57","doi-asserted-by":"publisher","unstructured":"Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017;9(407). https:\/\/doi.org\/10.1126\/scitranslmed.aal4712.","DOI":"10.1126\/scitranslmed.aal4712"},{"issue":"10","key":"3416_CR58","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.ajpath.2019.06.010","volume":"189","author":"M Wagner","year":"2019","unstructured":"Wagner M, Steinskog ES, Wiig H. Blockade of Lymphangiogenesis Shapes Tumor-Promoting Adipose Tissue Inflammation. Am J Pathol. 2019;189(10):2102\u201314. https:\/\/doi.org\/10.1016\/j.ajpath.2019.06.010.","journal-title":"Am J Pathol"},{"key":"3416_CR59","doi-asserted-by":"publisher","unstructured":"Liu J, Lin WP, Xiao Y, Yang QC, Bushabu Fidele N, Yu HJ, Sun ZJ. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma. Int Immunopharmacol 125 (Pt A). 2023;111128. https:\/\/doi.org\/10.1016\/j.intimp.2023.111128.","DOI":"10.1016\/j.intimp.2023.111128"},{"issue":"1","key":"3416_CR60","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong K-K, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. https:\/\/doi.org\/10.1038\/ncomms10501.","journal-title":"Nat Commun"},{"key":"3416_CR61","doi-asserted-by":"publisher","unstructured":"Martin AS, Molloy M, Ugolkov A, von Roemeling RW, Noelle RJ, Lewis LD, Johnson M, Radvanyi L, Martell RE. VISTA expression and patient selection for immune-based anticancer therapy. Front Immunol Volume. 2023;14\u20132023. https:\/\/doi.org\/10.3389\/fimmu.2023.1086102.","DOI":"10.3389\/fimmu.2023.1086102"},{"issue":"2","key":"3416_CR62","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.celrep.2019.12.036","volume":"30","author":"SR Rosenbaum","year":"2020","unstructured":"Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020;30(2):510\u2013e524516. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.036.","journal-title":"Cell Rep"},{"key":"3416_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-023-00691-z","volume":"5","author":"C Huang","year":"2024","unstructured":"Huang C, Wang X, Wang Y, Feng Y, Wang X, Chen S, Yan P, Liao J, Zhang Q, Mao C, Li Y, Wang L, Wang X, Yi W, Cai W-b, Chen S, Hong N, He W, Chen J, Jin W. Sirp\u03b1 on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47. Nat Cancer. 2024;5:1\u201317. https:\/\/doi.org\/10.1038\/s43018-023-00691-z.","journal-title":"Nat Cancer"},{"issue":"12","key":"3416_CR64","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.3390\/ijms24129945","volume":"24","author":"P Chmiel","year":"2023","unstructured":"Chmiel P, G\u0119ca K, Michalski A, K\u0142osi\u0144ska M, Kaczy\u0144ska A, Polkowski WP, Pelc Z, Sk\u00f3rzewska M. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors. Int J Mol Sci. 2023;24(12):9945.","journal-title":"Int J Mol Sci"},{"key":"3416_CR65","doi-asserted-by":"publisher","first-page":"115492","DOI":"10.1016\/j.bcp.2023.115492","volume":"210","author":"N Li","year":"2023","unstructured":"Li N, Yang S, Ren Y, Tai R, Liu H, Wang Y, Li J, Wang F, Xing J, Zhang Y, Zhu X, Xu S, Hou X, Wang G. Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha. Biochem Pharmacol. 2023;210:115492. https:\/\/doi.org\/10.1016\/j.bcp.2023.115492.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"3416_CR66","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s10528-024-10796-4","volume":"63","author":"M Ahmadpour Youshanlui","year":"2025","unstructured":"Ahmadpour Youshanlui M, Nasiri H, Valedkarimi Z, Sadeghi M, Akbari M, Motlagh Asghari K, Jamali F, Abdi D, Mehramouz B, Rasi Bonab F, Baradaran B. Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms. Biochem Genet. 2025;63(3):2263\u201375. https:\/\/doi.org\/10.1007\/s10528-024-10796-4.","journal-title":"Biochem Genet"},{"key":"3416_CR67","doi-asserted-by":"publisher","unstructured":"Rabadi D, Sajani A, Noelle R, Lines J. The role of VISTA in the tumor microenvironment. J Cancer Metastasis Treat. 2022;8. https:\/\/doi.org\/10.20517\/2394-4722.2022.06.","DOI":"10.20517\/2394-4722.2022.06"},{"issue":"21","key":"3416_CR68","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, Wang L. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015;112(21):6682\u20137. https:\/\/doi.org\/10.1073\/pnas.1420370112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3416_CR69","doi-asserted-by":"publisher","first-page":"115893","DOI":"10.1016\/j.celrep.2025.115893","volume":"44","author":"DK Nambiar","year":"2025","unstructured":"Nambiar DK, Maddineni S, Langthasa J, Cao H, Viswanathan V, Liu J, Islam MT, Mehta N, Frank J, Real A, Cheunkarndee T, Laseinde EE, Dharmadhikari B, Thakkar D, Boyd-Kirkup JD, Finegersh A, Divi V, Sunwoo JB, Aleman J, Wang XJ, Kong C, Xing L, Cochran JR, Le QT. VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response. Cell Rep. 2025;44(7):115893. https:\/\/doi.org\/10.1016\/j.celrep.2025.115893.","journal-title":"Cell Rep"},{"key":"3416_CR70","doi-asserted-by":"publisher","unstructured":"Duval KEA, Tavakkoli AD, Kheirollah A, Soderholm HE, Demidenko E, Lines JL, Croteau W, Zhang SC, Wagner RJ, Aulwes E, Noelle RJ, Hoopes PJ. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models. Int J Mol Sci. 2023;24(18). https:\/\/doi.org\/10.3390\/ijms241813742.","DOI":"10.3390\/ijms241813742"},{"issue":"1","key":"3416_CR71","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4(1):699. https:\/\/doi.org\/10.1038\/s42003-021-02191-1.","journal-title":"Commun Biol"},{"key":"3416_CR72","doi-asserted-by":"publisher","unstructured":"Iadonato S, Ovechkina Y, Lustig K, Cross J, Eyde N, Frazier E, Kabi N, Katz C, Lance R, Peckham D, Sridhar S, Talbaux C, Tihista I, Xu M, Guillaudeux T. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol Volume. 2023;14\u20132023. https:\/\/doi.org\/10.3389\/fimmu.2023.1311658.","DOI":"10.3389\/fimmu.2023.1311658"},{"issue":"3","key":"3416_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","volume":"42","author":"L Yuan","year":"2021","unstructured":"Yuan L, Tatineni J, Mahoney KM, Freeman GJ. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 2021;42(3):209\u201327. https:\/\/doi.org\/10.1016\/j.it.2020.12.008.","journal-title":"Trends Immunol"},{"key":"3416_CR74","doi-asserted-by":"publisher","unstructured":"Henry J, Patel M, Swiecicki P, Micaily I, Garmezy B, Banda K, Chaney M, Cohen J, Hayreh V, Lustig K, Ovechkina Y, Yu E, Iadonato S, Thierry G, Rosen L. 625 A phase 1\/2 clinical trial of antiVISTA \u2013 KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-sitc2024.0625.","DOI":"10.1136\/jitc-2024-sitc2024.0625"},{"key":"3416_CR75","doi-asserted-by":"publisher","first-page":"CT041","DOI":"10.1158\/1538-7445.AM2025-CT041","volume":"85","author":"J Henry","year":"2025","unstructured":"Henry J, Patel M, Swiecicki P, Micaily I, Garmezy B, Banda K, Chaney M, Cohen J, Hayreh V, Yu E, Iadonato S, Thierry G, Rosen L. Abstract CT041: Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors. Cancer Res. 2025;85:CT041\u2013041. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT041.","journal-title":"Cancer Res"},{"issue":"1","key":"3416_CR76","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biology. 2021;4(1):699. https:\/\/doi.org\/10.1038\/s42003-021-02191-1.","journal-title":"Commun Biology"},{"key":"3416_CR77","doi-asserted-by":"publisher","unstructured":"Noelle RJ, Lines JL, Lewis LD, Martell RE, Guillaudeux T, Lee SW, Mahoney KM, Vesely MD, Boyd-Kirkup J, Nambiar DK, Scott AM. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Front Oncol Volume. 2023;13\u20132023. https:\/\/doi.org\/10.3389\/fonc.2023.1225081.","DOI":"10.3389\/fonc.2023.1225081"},{"issue":"16suppl","key":"3416_CR78","doi-asserted-by":"publisher","first-page":"TPS2664","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2664","volume":"41","author":"JR Ahnert","year":"2023","unstructured":"Ahnert JR, Gruber JJ, Telli ML, Mita MM, Mita AC, Kim JW, Villalona-Calero MA, Patel M, Yadav SS, Sharma P, Haber T, Symons JL, Seet Q, Dharmadhikari B, Thakkar D, Kwek KY, DiMascio L, Rowinsky EK, Ingram P, Boyd-Kirkup JD. A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. J Clin Oncol. 2023;41(16suppl):TPS2664\u20132664. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2664.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3416_CR79","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3390\/molecules24152804","volume":"24","author":"B Musielak","year":"2019","unstructured":"Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, Stec M, Siedlar M, Holak TA, Plewka J. CA-170 \u2013 A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules. 2019;24(15):2804.","journal-title":"Molecules"},{"issue":"Suppl 3","key":"3416_CR80","doi-asserted-by":"publisher","first-page":"e000683","DOI":"10.1136\/esmoopen-2020-000683","volume":"4","author":"M Tagliamento","year":"2020","unstructured":"Tagliamento M, Bironzo P, Novello S. New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open. 2020;4(Suppl 3):e000683. https:\/\/doi.org\/10.1136\/esmoopen-2020-000683.","journal-title":"ESMO Open"},{"key":"3416_CR81","doi-asserted-by":"publisher","unstructured":"Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S, Tulsian NK, Gruber JJ, DiMascio L, Paszkiewicz KH, Ingram PJ, J DB-K. Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. J Immunother Cancer. 2022;10(2). https:\/\/doi.org\/10.1136\/jitc-2021-003382.","DOI":"10.1136\/jitc-2021-003382"},{"key":"3416_CR82","doi-asserted-by":"publisher","first-page":"1311658","DOI":"10.3389\/fimmu.2023.1311658","volume":"14","author":"S Iadonato","year":"2023","unstructured":"Iadonato S, Ovechkina Y, Lustig K, Cross J, Eyde N, Frazier E, Kabi N, Katz C, Lance R, Peckham D, Sridhar S, Talbaux C, Tihista I, Xu M, Guillaudeux T. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol. 2023;14:1311658. https:\/\/doi.org\/10.3389\/fimmu.2023.1311658.","journal-title":"Front Immunol"},{"key":"3416_CR83","doi-asserted-by":"publisher","unstructured":"Henry JT, Patel MR, Swiecicki PL, Micaily I, Garmezy B, Banda K, Chaney MF, Cohen J, Hayreh V, Lustig K, Ovechkina Y, Yu EY, Iadonato SP, Guillaudeux T, Rosen L. 625 A phase 1\/2 clinical trial of antiVISTA - KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors. J Immunother Cancer. 2024;12(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0625.","DOI":"10.1136\/jitc-2024-SITC2024.0625"},{"issue":"18","key":"3416_CR84","doi-asserted-by":"publisher","first-page":"13742","DOI":"10.3390\/ijms241813742","volume":"24","author":"KEA Duval","year":"2023","unstructured":"Duval KEA, Tavakkoli AD, Kheirollah A, Soderholm HE, Demidenko E, Lines JL, Croteau W, Zhang SC, Wagner RJ, Aulwes E, Noelle RJ, Hoopes PJ. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models. Int J Mol Sci. 2023;24(18):13742.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3416_CR85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-023-02083-y","volume":"21","author":"SH Kiaie","year":"2023","unstructured":"Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, Shokrollahi Barough M, Nasr MS, Sheibani M. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. J Nanobiotechnol. 2023;21(1):339. https:\/\/doi.org\/10.1186\/s12951-023-02083-y.","journal-title":"J Nanobiotechnol"},{"key":"3416_CR86","doi-asserted-by":"publisher","unstructured":"Moon TJ, Ta HM, Bhalotia A, Paulsen KE, Hutchinson DW, Arkema GM, Choi AS, Haynie MG, Ogunnaike L, Dever M, Wang LL, Karathanasis E. Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity. J Immunother Cancer. 2024;12(8). https:\/\/doi.org\/10.1136\/jitc-2024-008977.","DOI":"10.1136\/jitc-2024-008977"},{"issue":"1","key":"3416_CR87","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","volume":"15","author":"T Thisted","year":"2024","unstructured":"Thisted T, Smith FD, Mukherjee A, Kleschenko Y, Feng F, Jiang Z-G, Eitas T, Malhotra K, Biesova Z, Onumajuru A, Finley F, Cifuentes A, Zhang G, Martin GH, Takeuchi Y, Thiam K, Schreiber RD, van der Horst EH. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nat Commun. 2024;15(1):2917. https:\/\/doi.org\/10.1038\/s41467-024-47256-x.","journal-title":"Nat Commun"},{"key":"3416_CR88","doi-asserted-by":"publisher","first-page":"148043","DOI":"10.1016\/j.gene.2023.148043","volume":"896","author":"N Hosseinkhani","year":"2024","unstructured":"Hosseinkhani N, Hemmat N, Baghbani E, Baghbanzadeh A, Kazemi T, Mokhtarzadeh A, Jafarlou M, Amin Doustvandi M, Baradaran B. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development. Gene. 2024;896:148043. https:\/\/doi.org\/10.1016\/j.gene.2023.148043.","journal-title":"Gene"},{"key":"3416_CR89","doi-asserted-by":"publisher","first-page":"1466839","DOI":"10.3389\/fimmu.2024.1466839","volume":"15","author":"Y Duan","year":"2024","unstructured":"Duan Y, Ren X, Guo X, Xie J, Liu Z, Li L. VISTA in hematological malignancies: a review of the literature. Front Immunol. 2024;15:1466839. https:\/\/doi.org\/10.3389\/fimmu.2024.1466839.","journal-title":"Front Immunol"},{"key":"3416_CR90","doi-asserted-by":"publisher","first-page":"1225081","DOI":"10.3389\/fonc.2023.1225081","volume":"13","author":"RJ Noelle","year":"2023","unstructured":"Noelle RJ, Lines JL, Lewis LD, Martell RE, Guillaudeux T, Lee SW, Mahoney KM, Vesely MD, Boyd-Kirkup J, Nambiar DK, Scott AM. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Front Oncol. 2023;13:1225081. https:\/\/doi.org\/10.3389\/fonc.2023.1225081.","journal-title":"Front Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03416-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:37Z","timestamp":1792096897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":90,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3416"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03416-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human studies were performed for this review article.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation and revision of this manuscript, the authors used ChatGPT (OpenAI) to assist with language refinement and manuscript organization. The authors reviewed and edited all AI-assisted output and take full responsibility for the scientific content and final version of the manuscript.","order":3,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"280"}}